Vertex Pharmaceuticals Incorporated / Concert Pharmaceuticals, Inc.
2017 · Asset Purchase · $250M · Complete
Announcement Sentiment
100
Strongly positive
Vertex acquired worldwide development and commercialization rights to CTP-656, Concert's deuterated CFTR potentiator, for $160M upfront cash plus up to $90M in regulatory/reimbursement milestones (U.S., UK/Germany/France). The longer half-life potentiator was intended to enable once-daily dosing in CF triple-combination regimens. Closed July 2017.